Opinion
Video
Elias Jabbour, MD, provides an overview of the history of targeted agents and the use of tyrosine kinase inhibitors (TKIs) in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Mind the Gap: Patient-Reported PsA Impact Scores, Physician Treatment Decisions Misaligned
Five Years Later: Ongoing COVID-19 Challenges, Next Steps
Gynecologic Oncology Practices Evolve With Surgical De-Escalation Trends
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
AI Outperforms Traditional Methods in Predicting Ovarian Cancer Surgery Outcomes
Unmet Needs Remain in Secondary AML Following Treatment With HMAs